-
公开(公告)号：US20130102548A1
公开(公告)日：2013-04-25
申请号：US13555472
申请日：2012-07-23
IPC分类号： A61K9/00
CPC分类号： A61K9/0036 , A61K9/0034
摘要： A pharmaceutical formulation to treat vaginal conditions in a human patient comprises: at least one active agent; a modified release dosage form which provides extended release of the anti-infective agent upon vaginal administration to the patient; and wherein the formulation, when containing a total dose of the anti-infective agent of about 25 μg to about 500 mg based on the active agent will produce a plasma concentration versus time curve (ng/mL versus hours) having an area under the curve (AUC) of less than about 600 ng/mL·hr.
摘要翻译： 用于治疗人类患者的阴道病症的药物制剂包括：至少一种活性剂; 一种改良释放剂型，其在阴道给药时提供对抗感染药物的延长释放; 并且其中当基于活性剂含有约25至约500mg的总剂量的抗感染剂时，制剂将产生具有曲线下面积的血浆浓度对时间曲线（ng / mL对小时） （AUC）小于约600ng / mL·hr。
-
公开(公告)号：US5494681A
公开(公告)日：1996-02-27
申请号：US288849
申请日：1994-08-11
CPC分类号： A61K9/1617 , A61K9/1652
摘要： A substantially tasteless pharmaceutical delivery system, which comprises a) an active material; and b) a spatially oriented matrix comprising (i) a wax core material having a melting point within the range of about 50.degree. C. and about 200.degree. C.; and (ii) a regional hydrophobic polymer material and method for making the same.
摘要翻译： 一种基本无味的药物递送系统，其包括a）活性物质; 和b）空间取向的基质，其包含（i）熔点在约50℃和约200℃范围内的蜡芯材料; 和（ii）区域疏水性聚合物材料及其制造方法。
-
公开(公告)号：US5554380A
公开(公告)日：1996-09-10
申请号：US441297
申请日：1995-05-15
申请人： Robert C. Cuca , Keith S. Lienhop , Thomas C. Riley, Jr. , R. Saul Levinson , Mitchell I. Kirschner
发明人： Robert C. Cuca , Keith S. Lienhop , Thomas C. Riley, Jr. , R. Saul Levinson , Mitchell I. Kirschner
CPC分类号： A61K9/0058 , A61K9/006
摘要： A solid or semi-solid bioadherent, orally ingestible drug delivery system containing a water-in-oil system having at least two phases, one phase comprises from about 25% to about 75% by volume of an internal hydrophilic phase and the other phase comprises from about 25% to about 75% by volume of an external hydrophobic phase and wherein the external hydrophobic phase is comprised of three components, a) an emulsifier, b) a glyceride ester and c) a wax material.
摘要翻译： 包含至少两相的油包水系统的固体或半固体生物粘附的口服摄取药物递送系统，一相包含约25体积％至约75体积％的内部亲水相，而另一相包含 约25％至约75％体积的外部疏水相，并且其中所述外部疏水相由三种组分组成，a）乳化剂，b）甘油酯和c）蜡材料。
-
公开(公告)号：US08057433B2
公开(公告)日：2011-11-15
申请号：US11571863
申请日：2005-07-08
IPC分类号： A61M1/00
CPC分类号： A61M31/00
摘要： A pharmaceutical delivery system that releases an active agent in a controlled manner for an extended period in the vaginal cavity to treat or cure ailments associated with the vaginal cavity or proximal areas. The delivery system includes an applicator which is composed of a high internal phase emulsion, allowing the delivery system to adhere to the mueosal surfaces of the body, primarily the lining of vaginal cavity. The delivery system can maintain the high internal phase emulsion at a temperature of 86° F. for at least one month, without decomposition or instability of the emulsion.
摘要翻译： 药物递送系统，其以阴道腔中的受控方式长时间释放活性剂以治疗或治愈与阴道腔或近端区域相关的疾病。 递送系统包括由高内相乳液组成的施用器，允许递送系统粘附到身体的月球表面，主要是阴道腔的衬里。 输送系统可以将高内相乳液保持在86°F的温度下至少一个月，而不会使乳液分解或不稳定。
-
公开(公告)号：US20110276030A9
公开(公告)日：2011-11-10
申请号：US11571863
申请日：2005-07-08
IPC分类号： A61M31/00
CPC分类号： A61M31/00
摘要： A pharmaceutical delivery system that releases an active agent in a controlled manner for an extended period in the vaginal cavity to treat or cure ailments associated with the vaginal cavity or proximal areas. The delivery system includes an applicator which is composed of a high internal phase emulsion, allowing the delivery system to adhere to the mueosal surfaces of the body, primarily the lining of vaginal cavity. The delivery system can maintain the high internal phase emulsion at a temperature of 86° F. for at least one month, without decomposition or instability of the emulsion.
摘要翻译： 药物递送系统，其以阴道腔中的受控方式长时间释放活性剂以治疗或治愈与阴道腔或近端区域相关的疾病。 递送系统包括由高内相乳液组成的施用器，允许递送系统粘附到身体的月球表面，主要是阴道腔的衬里。 输送系统可以将高内相乳液保持在86°F的温度下至少一个月，而不会使乳液分解或不稳定。
-
公开(公告)号：US20080097388A1
公开(公告)日：2008-04-24
申请号：US11571863
申请日：2005-07-08
IPC分类号： A61M31/00
CPC分类号： A61M31/00
摘要： A pharmaceutical delivery system that releases an active agent in a controlled manner for an extended period in the vaginal cavity to treat or cure ailments associated with the vaginal cavity or proximal areas. The delivery system includes an applicator which is composed of a high internal phase emulsion, allowing the delivery system to adhere to the mueosal surfaces of the body, primarily the lining of vaginal cavity. The delivery system can maintain the high internal phase emulsion at a temperature of 86° F. for at least one month, without decomposition or instability of the emulsion.
摘要翻译： 药物递送系统，其以阴道腔中的受控方式长时间释放活性剂以治疗或治愈与阴道腔或近端区域相关的疾病。 递送系统包括由高内相乳液组成的施用器，允许递送系统粘附到身体的月球表面，主要是阴道腔的衬里。 输送系统可以将高内相乳液保持在86°F的温度下至少一个月，而不会使乳液分解或不稳定。
-
公开(公告)号：US09789057B2
公开(公告)日：2017-10-17
申请号：US13555472
申请日：2012-07-23
IPC分类号： A61K9/00
CPC分类号： A61K9/0036 , A61K9/0034
摘要： A pharmaceutical formulation to treat vaginal conditions in a human patient comprises: at least one active agent; a modified release dosage form which provides extended release of the anti-infective agent upon vaginal administration to the patient; and wherein the formulation, when containing a total dose of the anti-infective agent of about 25 μg to about 500 mg based on the active agent will produce a plasma concentration versus time curve (ng/mL versus hours) having an area under the curve (AUC) of less than about 600 ng/mL·hr.
-
公开(公告)号：US5858391A
公开(公告)日：1999-01-12
申请号：US864109
申请日：1997-05-28
申请人： Robert C. Cuca , Keith S. Lienhop , Thomas Charles Riley, Jr. , Mitchell I. Kirschner , R. Saul Levinson
发明人： Robert C. Cuca , Keith S. Lienhop , Thomas Charles Riley, Jr. , Mitchell I. Kirschner , R. Saul Levinson
CPC分类号： A61K9/006 , A61K9/0056 , A61K9/0058 , A61K9/0065
摘要： A bioadherent, orally ingestible system, which comprises: a water-in-oil emulsion system having at least two phases, one phase comprises from about 75% to about 99% by volume of an internal hydrophylic phase and the other phase comprises from about 25% to about 1% by volume of an external hydrophobic phase, wherein the external hydrophobic phase comprises two components, one component being about 3% to about 97% by volume of the hydrophobic phase of a hydrophobic oil and the other being about 97% to about 3% of an emulsifier having a HLB value less than about 10.
摘要翻译： 生物相容的口服摄取系统，其包含：具有至少两相的油包水乳液体系，一相包含约75体积％至约99体积％的内部亲水相，另一相包含约25 ％至约1体积％的外部疏水相，其中外部疏水相包含两种组分，一种组分为疏水相的疏水性油的约3％至约97体积％，另一种为约97％ 约3％HLB值小于约10的乳化剂。
-
公开(公告)号：US20130172279A1
公开(公告)日：2013-07-04
申请号：US13557527
申请日：2012-07-25
IPC分类号： A61K31/7056 , A61K9/00 , A61K31/4174
CPC分类号： A61K31/7056 , A61K9/0034 , A61K31/00 , A61K31/4174 , A61K31/56 , A61K31/7034 , A61K45/06 , A61K2300/00
摘要： A pharmaceutical composition comprises (a) an antibacterial agent in an antibacterially effective amount, illustratively comprising clindamycin or a pharmaceutically acceptable salt or ester thereof; and (b) an antifungal agent in an antifungally effective amount, illustratively comprising butoconazole or a pharmaceutically acceptable salt or ester thereof. The composition is adapted for application in a unit dose amount to a vulvovaginal surface and has at least one nonlipoidal internal phase and at least one lipoidal external phase that is bioadhesive to the vulvovaginal surface. The composition is useful for administration to a vulvovaginal surface to treat a mixed bacterial vaginosis and vulvovaginal candidiasis infection.
摘要翻译： 药物组合物包含（a）抗菌有效量的抗菌剂，例如包括克林霉素或其药学上可接受的盐或酯; 和（b）抗真菌有效量的抗真菌剂，例如包括布康唑或其药学上可接受的盐或酯。 该组合物适用于以外阴阴道表面的单位剂量施用，并且具有至少一个非脂性内相和至少一个与外阴阴道表面生物粘附的脂质外相。 该组合物可用于给予外阴阴道表面以治疗混合的细菌性阴道炎和外阴阴道念珠菌病感染。
-
公开(公告)号：US20110251141A1
公开(公告)日：2011-10-13
申请号：US13164326
申请日：2011-06-20
IPC分类号： A61K31/7056 , A61P31/00 , A61P31/04 , A61P15/02
CPC分类号： A61K31/7056 , A61K9/0034 , A61K31/00 , A61K31/4174 , A61K31/56 , A61K31/7034 , A61K45/06 , A61K2300/00
摘要： A pharmaceutical composition comprises (a) an antibacterial agent in an antibacterially effective amount, illustratively comprising clindamycin or a pharmaceutically acceptable salt or ester thereof; and (b) an antifungal agent in an antifungally effective amount, illustratively comprising butoconazole or a pharmaceutically acceptable salt or ester thereof. The composition is adapted for application in a unit dose amount to a vulvovaginal surface and has at least one nonlipoidal internal phase and at least one lipoidal external phase that is bioadhesive to the vulvovaginal surface. The composition is useful for administration to a vulvovaginal surface to treat a mixed bacterial vaginosis and vulvovaginal candidiasis infection.
摘要翻译： 药物组合物包含（a）抗菌有效量的抗菌剂，例如包括克林霉素或其药学上可接受的盐或酯; 和（b）抗真菌有效量的抗真菌剂，例如包括布康唑或其药学上可接受的盐或酯。 该组合物适用于以外阴阴道表面的单位剂量施用，并且具有至少一个非脂性内相和至少一个与外阴阴道表面生物粘附的脂质外相。 该组合物可用于给予外阴阴道表面以治疗混合的细菌性阴道炎和外阴阴道念珠菌病感染。
-
-
-
-
-
-
-
-
-
搜索结果
20 条记录 (耗时 0.018 秒)